Re­meGen read­ies $514M IPO as HKEX adds jew­el to the crown

Nas­daq may boast of a biotech boom with the sheer num­ber of com­pa­nies in its IPO queue. But when it comes to chart-top­ping hauls, HKEX ap­par­ent­ly takes the crown.

The lat­est record set­ter is Re­meGen, a Yan­tai, Shan­dong-based biotech that — months af­ter draw­ing in a stel­lar slate of crossover in­vestors for a $100 mil­lion-plus round — is set to raise up to $514 mil­lion from its pub­lic de­but in Hong Kong.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.